🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🥁🥁🥁 Thrilled to share that our latest paper is now OUT 📢🥳 🎉It is a distinct honor to share an article with esteemed scholars whose work has profoundly shaped the #ProstateCancer from the past to the future🔝🔝🔝 🎯Key findings from meta-analysis of 3 pioneer trials

According to phase 2/3 AGITG DYNAMIC-III: Colon cancer & 🧬🩸ctDNA: a warning signal. ctDNA is prognostic—not predictive for chemo escalation. Biology speaks louder than stage. Time to rethink adjuvant strategies. ASCO OncoAlert #ASCO25

Excited to share this collaborative effort as a poster at #ASCO2025 ASCO 🎯 SARS-CoV-2 mRNA-BNT162b2 vaccination is associated with improved PFS and OS in mCRC patients treated with bevacizumab, suggesting potential synergy between the vaccine and cancer therapy. ✅ Clinicians

Huge congrats to our rising stars✨✨✨ Beliz Bahar Karaoğlan and Coskun YAZGAN on their poster at #ASCO25 ASCO OncoAlert OncLive.com Yüksel Ürün

🚨 Our new study alert! Elsevier What is the role of comorbidity burden in response to immunotherapy based combos in patients with metastatic renal cell carcinoma? 🎯Endpoints : Overall surival and time to treatment failure High comorbidity 🟰 Worse Outcomes ❓❗️No

Meta-analysis of 343 transplant recipients w/ advanced cancer treated w/ immune checkpoint inhibitors: 🟰53% cancer deaths at 3 yrs 🟰1-yr survival: 57% (cutaneous SCC), 48% (melanoma), 27% (other solid cancers) 🟰36% acute rejection, 18% graft loss ✅Steroids + mTOR inhibitors

🛑A meta-analysis from the DADSPORT Collaboration: Adding hormone therapy to post-op radiotherapy in nonmetastatic prostate cancer improves: ✅ Metastasis-free survival (HR=0.78) ✅ Prostate cancer–specific survival (HR=0.61) 📉 Overall survival benefit small (HR=0.86), limited

🚨 Just published in The Oncologist ! 🥁Our new study from "Turkish Oncology Group Kidney Cancer Consortium" database... 🚭 Still smoking? It’s costing lives. ❌In metastatic #KidneyCancer , current smokers on immune checkpoint inhibitors had: 🔻Shorter TTF: 4.1 vs. 10.8 months

🚨Just weeks after #ASCO25, the latest highlights in genitourinary cancers are now available. The newly released The ASCO Post provides a quick and concise overview. 👀Take another look, this time from our perspective w/ Yüksel Ürün 👉bit.ly/46lgtHK ASCO

"“Kidney cancer is at a pivotal turning point, with new long-term data and novel therapies shaping the future of care.” -EMRE YEKEDÜZ, MD, AND YÜKSEL ÜRÜN, MD" ascopost.com/news/june-2025… via @ascopost Emre Yekedüz

"“Significant advancements in prostate cancer emphasized treatment intensification and precision-based strategies for localized and castration-sensitive disease.” -EMRE YEKEDÜZ, MD, AND YÜKSEL ÜRÜN, MD" ascopost.com/news/june-2025… via @ascopost Emre Yekedüz

Dear Colleague, We invite you to join the Prostate Cancer Care Disparity Analysis Project (ProGAP) — [NCT06612034] — by completing our brief 6–8 minute survey exploring global disparities in prostate cancer treatment. Your voice is essential to shaping more equitable care

Dear Colleague, Join the Prostate Cancer Care Disparity Analysis Project (ProGAP) (NCT06612034) by taking our quick 6–8 minute survey on global disparities in prostate cancer treatment. Your input is vital in shaping better care. Thank you! Link👇👇👇 qualtricsxmvcbtqb5rf.qualtrics.com/jfe/form/SV_7a…

Happy to share our insights in this invited commentary published in "Kidney Cancer" Huge congrats our rising ⭐️⭐️⭐️ fellow Hatice Bölek from Ankara Üniversitesi ! ⁉️Immunotherapy re-challenge appears to have limited efficacy in kidney cancer. What might be the underlying reasons from

🚨 New Era with biomarker-driven trials in Prostate Cancer Therapy lies ahead! 🧬Molecular stratification is revolutionizing metastatic prostate cancer treatment. From ARPIs to PARP inhibitors (BRCA2/PALB2), ICIs (MMRd), and PSMA-targeted therapies, novel targets like EZH2,

🚨 New study alert! 🧪 In our multicenter study of mCRPC patients, we evaluated the impact of enzalutamide vs. abiraterone acetate in the immediately preceding line before ¹⁷⁷Lu-PSMA-617 therapy. 📊 Striking difference in overall survival: ✨ 12.8 months with prior

Congrats to rising star Coskun YAZGAN and every colleague on this great study tackling a real clinical question for patients with mCRPC. Curiosity, teamwork, and care move science forward. Proud of our team’s work! #Oncology #ProstateCancer The Oncologist Advanced Prostate Cancer Consensus Conference OncoAlert

🚨 New publication alert! 💊Enzalutamide before ☢️¹⁷⁷Lu-PSMA-617 improves OS vs. abiraterone in mCRPC. Stronger PSMA expression, better sequencing and survival! The Oncologist OncoAlert Advanced Prostate Cancer Consensus Conference Coskun YAZGAN Hatice Bölek Mehmet Ali Nahit Sendur deniztural Emre Yekedüz